- |||||||||| enapotamab vedotin (HuMax-AXL-ADC) / Genmab
Evaluating the potential of radiomics features to predict outcome to an antibody-drug conjugate therapy in non-small cell lung cancer patients (Section 46) - Mar 5, 2024 - Abstract #AACR2024AACR_3841;
P1/2
This study evaluated radiomics, a non-invasive biomarker, for assessment of tumor heterogeneity in non-small cell lung cancer (NSCLC) patients treated with an AXL-targeting antibody-drug conjugate (ADC), enapotamab vedotin (EnaV), through analyzing baseline and post-treatment radiomic features from CT images for predicting outcome.Clinical development of EnaV was discontinued in 2020 due to low response rates unimproved by dose optimization and/or predictive biomarkers...Cancer Res. 2021
- |||||||||| enapotamab vedotin (HuMax-AXL-ADC) / Genmab
Trial completion, Trial primary completion date: Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors (clinicaltrials.gov) - Dec 9, 2021
P1/2, N=306, Completed,
This study provides a preclinical rationale for the evaluation of AXL-targeting ADCs in the treatment of AXL-expressing sarcomas. Active, not recruiting --> Completed | Trial primary completion date: Aug 2021 --> Nov 2021
- |||||||||| enapotamab vedotin (HuMax-AXL-ADC) / Genmab, Seagen
Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade. (Pubmed Central) - Aug 13, 2021
Here, we show that enapotamab vedotin (EnaV), an antibody-drug conjugate targeting AXL, effectively targets tumors that display insensitivity to immunotherapy or tumor-specific T cells in several melanoma and lung cancer models...Combining EnaV with tumor-specific T cells proved superior to either treatment alone in models of melanoma and lung cancer and induced ICB benefit in models otherwise insensitive to anti-PD-1 treatment. Our findings indicate that targeting AXL-expressing, immunotherapy-resistant tumors with EnaV causes an immune-stimulating tumor microenvironment and enhances sensitivity to ICB, warranting further investigation of this treatment combination.
- |||||||||| enapotamab vedotin (HuMax-AXL-ADC) / Genmab
Enrollment closed, Trial completion date, Trial primary completion date: Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors (clinicaltrials.gov) - Jul 2, 2021
P1/2, N=374, Active, not recruiting,
Our findings indicate that targeting AXL-expressing, immunotherapy-resistant tumors with EnaV causes an immune-stimulating tumor microenvironment and enhances sensitivity to ICB, warranting further investigation of this treatment combination. Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Feb 2021 --> Aug 2021
- |||||||||| enapotamab vedotin (HuMax-AXL-ADC) / Genmab, Seagen, tisotumab vedotin (HuMax-TF-ADC) / Genmab, Seagen
[VIRTUAL] The making of an ADC (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_196;
In the road-map to developing an ADC, understanding target biology and selecting the most optimal antibody, linker and toxic payload represent critical parameters. This talk will provide an overview of this thought process in the context of the development of two ADCs currently in the clinic, tisotumab vedotin and enapotamab vedotin.
- |||||||||| enapotamab vedotin (HuMax-AXL-ADC) / Genmab, Seattle Genetics
Enapotamab Vedotin (STARLIGHT BALLROOM) - Feb 21, 2020 - Abstract #IASLCLCTT2020IASLC_LCTT_203;
- |||||||||| enapotamab vedotin (HuMax-AXL-ADC) / Genmab, Seattle Genetics
Journal, Heterogeneity: Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. (Pubmed Central) - May 9, 2019
Furthermore, by inducing AXL transcription, BRAF/MEK inhibitors potentiated the efficacy of AXL-107-MMAE. These findings provide proof of concept for the premise that rationalized combinatorial targeting of distinct populations in heterogeneous tumors may improve therapeutic effect, and merit clinical validation of AXL-107-MMAE in both treatment-naive and drug-resistant cancers in mono- or combination therapy.
- |||||||||| enapotamab vedotin (HuMax-AXL-ADC) / Genmab
Enrollment change: Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors (clinicaltrials.gov) - May 2, 2018
P1/2, N=292, Recruiting,
These findings provide proof of concept for the premise that rationalized combinatorial targeting of distinct populations in heterogeneous tumors may improve therapeutic effect, and merit clinical validation of AXL-107-MMAE in both treatment-naive and drug-resistant cancers in mono- or combination therapy. N=165 --> 292
|
